Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Fluconazole 200mg
Ipca Pharma (NZ) Pty Limited
Fluconazole 200 mg
200 mg
Capsule
Active: Fluconazole 200mg Excipient: Colloidal silicon dioxide Erythrosine Gelatin Indigo carmine Lactose Magnesium stearate Maize starch Methyl hydroxybenzoate Propyl hydroxybenzoate Purified water Sodium laurilsulfate Titanium dioxide
Blister pack, Alu foil and PVC/PVDC Alu foil, 7 capsules
Prescription
Prescription
Mylan Laboratories Limited
Fluconazole capsules are indicated for the treatment of Cryptococcosis
Package - Contents - Shelf Life: Blister pack, Alu foil and PVC/PVDC Alu foil - 7 capsules - 36 months from date of manufacture stored at or below 25°C - Blister pack, Alu foil and PVC/PVDC Alu foil - 10 capsules - 36 months from date of manufacture stored at or below 25°C - Blister pack, Alu foil and PVC/PVDC Alu foil - 14 capsules - 36 months from date of manufacture stored at or below 25°C - Blister pack, Alu foil and PVC/PVDC Alu foil - 20 capsules - 36 months from date of manufacture stored at or below 25°C - Blister pack, Alu foil and PVC/PVDC Alu foil - 28 capsules - 36 months from date of manufacture stored at or below 25°C - Blister pack, Alu foil and PVC/PVDC Alu foil - 40 capsules - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 50 capsules - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 100 capsules - 24 months from date of manufacture stored at or below 25°C
2009-12-08
Version 1.0 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Ipca- Fluconazole, 50 mg, 150 mg and 200 mg, capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg, 150 mg or 200 mg of fluconazole. Excipient with known effect:lactose, methyl hydroxybenzoate, propyl hydroxybenzoate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule 50 mg: Size ‘4’ capsules with a white body and a blue cap and are filled with a white homogenous white to off white powder which contains 50 mg fluconazole. Capsule 150 mg: Size ‘1’ capsules with a blue body and cap and are filled with a white homogenous white to off white powder which contains 150 mg fluconazole. Capsule 200 mg: Size ‘0’ capsules with a white body and a purple cap and are filled with a white homogenous white to off white powder which contains 200 mg fluconazole. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Fluconazole Capsules are indicated for the treatment of the following conditions: ● Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). Normal hosts, and patients with AIDS, organ transplants or other causes of immunosuppression may be treated. Fluconazole capsules can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS. ● Systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. Patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. ● Mucosal candidiasis. These include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune function may be treated. ● Vaginal candidiasis, acute or recurrent. Read the complete document